מתוך medicontext.co.il
LONDON (Reuters Health) – When administered to infants, the conjugate group C meningococcal vaccine causes few adverse events, most of which are considered mild, according to results of a prospective study conducted in the UK.
Dr. Adam Finn, now with the University of Bristol, and colleagues followed 2796 infants who received up to three immunisations with the new vaccine, Chiron Men C, along with their routine immunisations. The Men C vaccinations were scheduled to be given at ages 2, 3, and 4 months.
As reported in the Archives of Disease in Childhood for November, 49 infants (1.8%) experienced 58 adverse events judged to be possibly, probably, or definitely related to the meningococcal C vaccine. No serious adverse events were considered to be probably or definitely related to the vaccine.
Four serious adverse events were considered possibly related. These included a hypotonic hyporesponsive episode 4 hours after the first dose of the study vaccine and other routine immunisations, a moderate non-specific screaming episode that lasted longer than 6 hours starting a few hours after the first doses, a red maculopapular rash that developed 4 days after vaccination, and a case of irritability and ear-pulling after administration of a second doses.
The British research team notes that the screaming syndrome, hypotonic episode, and agitation "are well recognised to be associated with diphtheria, tetanus, whole cell pertussis immunisation, which was given along with the Men C vaccine in this study."
Only four events were judged to be definitely related to the vaccine, and all involved injection site reactions.
"Within constraints of the study design it certainly seemed to be safe," Dr. Finn told Reuters Health. He added that "it's a vaccine that is being given to all children in the UK, and has been since the end of 1999, so there has been a great deal more experience, just from general use, suggesting the same thing."




תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!